Table 1 Patient and treatment characteristics
Characteristics | Values (range or percentage) |
|---|---|
Median age (years) | 62 (33–78) |
Age (years) | |
 31–40 | 3 (12.0%) |
 41–50 | 1 (4.0%) |
 51–60 | 8 (32.0%) |
 61–70 | 10 (40.0%) |
 71–80 | 3 (12.0%) |
FIGO stage (2018) | |
 1 | 15 (60.0%) |
 2 | 2 (8.0%) |
 3 | 7 (28.0%) |
 4 | 1 (4.0%) |
Median body mass index prior to RT (kg/m2) | 25.0 (18.2–41.6) |
Median Karnofsky performance score prior to RT (%) | 90 (70–100) |
Type of surgery | |
 TAH-BSO with LND | 18 (72.0%) |
 TAH-BSO without LND | 1 (4.0%) |
 TLH-BSO with LND | 6 (24.0%) |
Prior surgical lymph node dissection | |
 Yes | 24 (96.0%) |
 No | 1 (4.0%) |
Median time from surgery to RT start | 85 (36–232) |
Chemotherapy | |
 Simultaneous (cisplatin weekly) | 7 (28.0%) |
 Prior to radiotherapy (carboplatin/paclitaxel) | 8 (32.0%) |
 After radiotherapy (carboplatin/paclitaxel) | 5 (20.0%) |
 No chemotherapy | 5 (20.0%) |
Median RT treatment time (days) | 43 (33–51) |
Proton beam therapy dose | |
 45.0 GyRBE | 9 (36.0%) |
 50.4 GyRBE | 16 (64.0%) |
Extended field radiation | |
 Including para-aortic region | 1 (4.0%) |
 No extended para-aortic field | 24 (96.0%) |